Journal article

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer

MH Kershaw, JT Jackson, NM Haynes, MWL Teng, M Moeller, Y Hayakawa, SE Street, R Cameron, JE Tanner, JA Trapani, MJ Smyth, PK Darcy

JOURNAL OF IMMUNOLOGY | AMER ASSOC IMMUNOLOGISTS | Published : 2004

Abstract

The major limiting factor in the successful application of adjuvant therapy for metastatic disease is the lack of adjuvant specificity that leads to severe side effects. Reasoning that T cells of the immune system are highly specific, we generated tumor-specific T cells by genetic modification of mouse primary T cells with a chimeric receptor reactive with the human breast cancer-associated Ag erbB-2. These T cells killed breast cancer cells and secreted IFN-gamma in an Ag-specific manner in vitro. We investigated their use against metastatic breast cancer in mice in an adjuvant setting, and compared their effectiveness with the commonly applied adjuvants doxorubicin, 5-fluorouracil, and her..

View full abstract